Devyser Q1 - A most exciting year

Redeye reiterates its base case following the company’s Q1 report. We anticipated a soft quarter but see good prospects for an exceptionally strong H2 2025. There is a hefty upside to our DCF base case at current levels, and the shares are trading at undemanding multiples. We see reimbursement, quarterly reports and FDA timeline as key catalysts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/